替吉奥联合艾迪注射液治疗晚期胃癌的Meta分析

发布时间：2018-11-14 14:55

【摘要】：目的:系统评价替吉奥联合艾迪注射液治疗晚期胃癌的疗效和安全性,为临床提供循证参考。方法:计算机检索相关期刊论文(CJFD)、万方数据库、中文科技期刊数据库(VIP)、中国生物医学文献数据库(CBM)、Cochrane图书馆、PubMed和EMBase,收集替吉奥联合艾迪注射液(试验组)对比替吉奥单药(对照组)治疗晚期胃癌的临床随机对照试验(RCT),提取资料并按照Cochrane系统评价员手册5.1.0提供的偏倚风险评估工具评价质量后,采用RevMan 5.3软件进行Meta分析。结果:最终纳入8项RCT,共计690例患者。Meta分析结果显示,两组有效率比较,差异无统计学意义[OR=1.19,95%CI(0.88,1.61),P=0.26];试验组患者生存质量改善率[OR=3.62,95%CI(2.48,5.30),P0.001]、免疫细胞水平[CD3:SMD=1.31,95%CI(1.06,1.56),P0.001;CD4:SMD=1.71,95%CI(1.38,2.04),P0.001;CD8:SMD=-1.46,95%CI(-1.68,-1.23),P0.001;CD4/CD8:SMD=1.45,95%CI(1.14,1.76),P0.001]显著优于对照组,白细胞减少发生率[RR=0.52,95%CI(0.40,0.68),P0.001]、血小板减少发生率[RR=0.49,95%CI(0.36,0.67),P0.001]、消化道障碍发生率[RR=0.56,95%CI(0.43,0.71),P0.001]均显著低于对照组,差异均有统计学意义。结论:与单用替吉奥相比,替吉奥联合艾迪注射液治疗晚期胃癌未能明显提高实体瘤治疗效果,但是可以显著改善患者生存质量与免疫力,减少不良反应的发生。
[Abstract]:Objective: to evaluate the efficacy and safety of tigueo combined with Aidi injection in the treatment of advanced gastric cancer and to provide evidence-based reference for clinical practice. Methods: the full text database of Chinese periodicals, (CJFD), Wanfang database, Chinese sci-tech journal database (VIP), Chinese biomedical literature database (CBM), Cochrane library, PubMed and EMBase, were searched by computer. Clinical randomized controlled trial (RCT),) of tigueo combined with Aidi injection in the treatment of advanced gastric cancer compared with tigeol alone (control group) After extracting the data and evaluating the quality according to the bias risk assessment tool provided by Cochrane system evaluator manual 5.1.0, the Meta analysis was carried out with RevMan 5.3 software. Results: a total of 690 patients were included in 8 items of RCT,. The results of Meta analysis showed that there was no significant difference in the effective rate between the two groups [OR=1.19,95%CI (0.881.61), OR=1.19,95%CI 0.26]; In the test group, the improvement rate of quality of life [OR=3.62,95%CI (2.48 卤5.30), P0.001], the level of immune cell [CD3:SMD=1.31,95%CI (1.06 卤1.56), P 0.001] CD4: SMD1.71% 95 CI (1.38 卤2.04), P0.001; CD8:SMD=-1.46,95%CI (-1.68 ~ 1.23), P 0.001; CD4/CD8:SMD=1.45,95%CI (1.14 卤1.76), P0.001] was significantly higher than the control group, the incidence of leukopenia [RR=0.52,95%CI (0.40 卤0.68), P0.001], The incidence of thrombocytopenia [RR=0.49,95%CI (0.36 卤0.67), P0.001], gastrointestinal disorders [RR=0.56,95%CI (0.43n 0.71), P0.001] were significantly lower than those in the control group (P 0.001). Conclusion: compared with the treatment of advanced gastric cancer treated with tigeo and Aidi injection alone, the therapeutic effect of Tigeo combined with Aidi injection can not improve the quality of life and immunity of patients, and reduce the occurrence of adverse reactions.
【作者单位】：南京中医药大学中医药文献研究所/江苏省中医药防治肿瘤协同创新中心;
【基金】：江苏高校协同创新中心课题(No.苏政办发[2014]22号) 江苏省优势学科建设工程项目(No.苏政办发[2014]37号)
【分类号】：R735.2

【相似文献】